Product mentioned on podcasts
BPC-157
Mentioned on 7 episodes by 5 guests across our covered podcasts.
SignalCast may earn commission on purchases via these links. As an Amazon Associate, SignalCast earns from qualifying purchases.
Who mentioned it
“Internal medicine physician Dr. Abud Bakri provides a clinical framework for understanding peptides, covering BPC-157's origins in Croatian gastric research, growth hormone secretagogues like tesamorelin and MK-677, the tripeptides EDR (pinealon) and GHK-copper”
Mentioned on: Huberman Lab“seven peptides—including BPC-157 and TB-500—are scheduled for re-legalization review in July 2025. BPC-157, for example, has no established LD-1 dose, meaning researchers cannot determine a quantity harmful to even 1% of test subjects, making it among the most well-tolerated compounds studied in animal models.”
Mentioned on: The Diary of a CEO“BPC-157 carries additional red flags: it is not encoded in the human genome, has no identified receptor, has no known mechanism of action, and all published data originate from a single investigator whose findings have not been independently reproduced.”
Mentioned on: The Peter Attia Drive“BPC-157 shows no recorded human fatalities but poses tumor vascularization risk, making short-term injury use a more defensible application than chronic systemic dosing.”
Mentioned on: a16z Podcast“BPC-157, the flagship peptide in self-administration stacks, has a half-life measured in seconds after injection, leaving no pharmacological window to produce therapeutic effects.”
Mentioned on: a16z Podcast